Zacks Investment Research Lowers INDIVIOR PLC/S (INVVY) to Sell

Zacks Investment Research cut shares of INDIVIOR PLC/S (OTCMKTS:INVVY) from a hold rating to a sell rating in a research note released on Tuesday morning.

According to Zacks, “Indivior PLC operates as a specialty pharmaceutical company. It is engaged in discovering and developing medications and treatment for alcohol addiction, opioid overdose, cocaine intoxication and co-occurring conditions, such as schizophrenia. The Company markets and promotes SUBOXONE (buprenorphine and naloxone) Sublingual Film, SUBOXONE (buprenorphine and naloxone) Sublingual Tablet, and SUBUTEX (buprenorphine) Sublingual Tablet, each buprenorphine-based treatment for opioid. Indivior PLC is based in United States. “

INVVY has been the subject of a number of other research reports. ValuEngine cut INDIVIOR PLC/S from a hold rating to a sell rating in a research report on Wednesday, July 11th. Citigroup reaffirmed a neutral rating on shares of INDIVIOR PLC/S in a research report on Thursday, May 31st.

Shares of OTCMKTS:INVVY opened at $12.17 on Tuesday. INDIVIOR PLC/S has a fifty-two week low of $12.15 and a fifty-two week high of $33.83. The stock has a market capitalization of $2.46 billion, a price-to-earnings ratio of 6.76, a P/E/G ratio of 0.86 and a beta of 0.77.

INDIVIOR PLC/S (OTCMKTS:INVVY) last announced its quarterly earnings results on Thursday, July 26th. The company reported $0.45 earnings per share for the quarter. The company had revenue of $268.00 million during the quarter. sell-side analysts expect that INDIVIOR PLC/S will post 1.74 EPS for the current fiscal year.

INDIVIOR PLC/S Company Profile

Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. The company's product pipeline focuses on treating opioid use disorder, alcohol use disorder, overdose rescue, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex.

Featured Article: Average Daily Trade Volume – ADTV

Get a free copy of the Zacks research report on INDIVIOR PLC/S (INVVY)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for INDIVIOR PLC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INDIVIOR PLC/S and related companies with's FREE daily email newsletter.

Leave a Reply